Purespring Therapeutics presents new preclinical data on novel gene therapy for IgA Nephropathy at ASN Kidney Week 2024 Results from the study underpin the potential of Purespring’s lead AAV gene therapy programme, PS-002, as an important novel modality to treat IgAN Data support progression towards a Phase I/II...